Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base

Cancer

Volumn 121, Issue 23, 2015, Pages 4141-4149

  Rutter, Charles E ^a   Park, Henry S ^a   Corso, Christopher D ^a   Lester Coll, Nataniel H ^a   Mancini, Brandon R ^a   Yeboa, Debra N ^a   Johung, Kimberly L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chemoradiation; chemotherapy; pancreatic; radiation

Indexed keywords

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; SURVIVAL; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84948585742     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29652     Document Type: Article

References (34)

1. National Cancer Institute. SEER Stat Fact Sheets: Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed February 9, 2015.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
4. Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17:981-990.
5. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10: 511-518.
6. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010; 28:4450-4456.
7. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
8. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
9. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
10. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 1999;230: 776-782.
11. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026.
12. Hazard L. The role of radiation therapy in pancreas cancer. Gastrointest Cancer Res. 2009;3:20-28.
13. Yovino S, Maidment BW III, Herman JM, et al. Analysis of local control in patients receiving IMRT for resected pancreatic cancers. Int J Radiat Oncol Biol Phys. 2012;83:916-920.
14. Abrams RA, Winter KA, Regine WF, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704-A phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2012;82: 809-816.
15. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
16. Berger AC, Winter K, Hoffman JP, et al. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9-90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012;84:e291-e297.
17. Kinsella TJ, Seo Y, Willis J, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31:446-453.
18. Park HS, Gross CP, Makarov DV, Yu JB. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:1365-1373.
19. Crane CH, Iacobuzio-Donahue CA. Keys to personalized care in pancreatic oncology. J Clin Oncol. 2012;30:4049-4950.
20. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score Surveillance, Epidemiology, and End Results database analysis. J Surg Oncol. 2014;110: 960-966.
21. Kooby D, Gillespie T, Liu Y, et al. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the National Cancer Data Base. Ann Surg Oncol. 2013;20: 3634-3642.
22. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg. 1993;217:144-148.
23. Gnerlich JL, Luka SR, Deshpande AD, et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch Surg. 2012;147:753-760.
24. Stocken DD, Buchler MW, Dervenis C, et al. Meta-Analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-1381.
25. Takahashi H, Ohigashi H, Ishikawa O, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabinebased chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255:95-102.
26. ClinicalTrials.gov. Gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that has been removed by surgery. https://clinicaltrials.gov/ct2/show/NCT01013649. Accessed February 25, 2015.
27. Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer. 2007;110:47-55.
28. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326-331.
29. Crane CH, Ben-Josef E, Small Jr. W. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350:2713-2715.
30. Bydder S, Spry N. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350:2713-2715.
31. Morris SL, Beasley M, Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med. 2004;350:2713-2715.
32. Choti MA. Adjuvant therapy for pancreatic cancer-Dhe debate continues. N Engl J Med. 2004;350:1249-1251.
33. Chuong MD, Boggs DH, Patel KN, Regine WF. Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? J Gastrointest Oncol. 2014;5:166-177.
34. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835-844.